857334-77-1

Basic information

• Product Name: (R)-benzyl 2-(4-benzyl-3,6-dioxopiperazin-2-yl)acetate
• Synonyms: (R)-benzyl 2-(4-benzyl-3,6-dioxopiperazin-2-yl)acetate
• CAS NO: 857334-77-1
• Molecular Weight: 352.39
• Mol File: 857334-77-1.mol

Chemical Properties

• CAS DataBase Reference: (R)-benzyl 2-(4-benzyl-3,6-dioxopiperazin-2-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-benzyl 2-(4-benzyl-3,6-dioxopiperazin-2-yl)acetate(857334-77-1)
• EPA Substance Registry System: (R)-benzyl 2-(4-benzyl-3,6-dioxopiperazin-2-yl)acetate(857334-77-1)

Safety Data

• Hazardous Substances Data: 857334-77-1(Hazardous Substances Data)

Upstream product

• 51186-58-4 4-benzyl Boc-D-aspartate 
• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 857334-78-2 C₂₅H₂₈N₂O₆ 

Downstream Products

• 857334-79-3 (R)-2-(4-benzylpiperazin-2-yl)ethanol 
• 1272421-10-9 (R)-tert-butyl 3-(2-hydroxyethyl)piperazine-1-carboxylate 
• 660862-46-4 (R)-2-(piperazin-2-yl)ethan-1-ol 

Relevant articles and documents

5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE

The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a 5-HT2C receptor-mediated disorder, such as, weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction and the like, obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders, urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a compound herein, optionally in combination with a supplemental agent.

Asymmetric syntheses of (R)-4-halo-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines, important 5-HT2C agonist precursors

Asymmetric syntheses of N-protected (R)-4-halo-6,6a,7,8,9,10-hexahydro-5H-pyrazino[1,2-a][1,n]naphthyridines, advanced intermediates for the synthesis of highly potent and selective 5-HT2C agonists, are described. The key transformation involves ring opening of N-protected bicyclic sulfamidate (R)-hexahydro-3H-pyrazino[1,2-c][1,2,3]oxathiazine 1,1-dioxide with (4-halo-2-fluoropyridin-3-yl)lithiums or (3-bromo-5-fluoropyridin-4-yl)lithium. In situ hydrolyses of the resultant sulfamic acids and subsequent intramolecular nucleophilic aromatic substitutions (SNAr) produce the enantiopure tricycles. The two step procedure represents new methodology for the stereoselective syntheses of tetrahydronaphthyridines.

NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

Acetylcholine receptor ligands of formula (I), wherein D, Ar1, E and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for usi